Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. Chief Legal Officer Boughton Soleil sold 4,651 shares of Class A common stock in an open-market transaction. The shares were sold at an average price of
Hims & Hers Health, Inc. reported that Chief Financial Officer Oluyemi Okupe acquired 410,690 shares of Class A common stock through earned performance-based restricted stock units. The Compensation Committee certified the performance goals on February 23, 2026, and the related shares are scheduled to be delivered around March 15, 2026.
Hims & Hers Health, Inc. reported that Chief Legal Officer Boughton Soleil acquired 273,794 shares of Class A common stock through a performance-based restricted stock unit (PRSU) award. The award carried a price of $0.00 per share and lifted Soleil’s directly held stake to 445,623 shares.
The PRSUs were earned under a previously granted award after the Compensation Committee certified that the performance criteria were met as of February 23, 2026. Under the award terms, the underlying shares are scheduled to be delivered to Soleil on or about March 15, 2026.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported acquiring 365,058 shares of Class A common stock through earned performance-based restricted stock units (PRSUs). These PRSUs were previously granted and each unit represents the right to receive one share.
The Compensation Committee certified that the award's performance criteria were met as of February 23, 2026, and the shares are scheduled to be delivered to Chi on or about March 15, 2026. Following this grant, his direct holdings total 670,219 shares of Class A common stock.
Hims & Hers Health, Inc. reported that Chief Executive Officer Andrew Dudum acquired 794,002 shares of Class A common stock through the earning of performance-based restricted stock units (PRSUs). The award carried a grant price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These PRSUs were earned after the Compensation Committee certified that the performance criteria for the award were met as of February 23, 2026. Each PRSU converts into one share of Class A common stock, and the shares are scheduled to be delivered to Dudum on or about March 15, 2026. Following this acquisition, he directly holds 1,672,734 Class A shares, alongside additional indirect holdings through various family and estate planning trusts.
Hims & Hers Health, Inc. presents its Annual Report describing a fast‑growing, consumer‑focused telehealth and wellness platform built around subscription treatments for chronic conditions such as sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. The company combines licensed Affiliated Medical Groups, wholly owned pharmacies, a 503B outsourcing facility, peptide manufacturing, and a new laboratory testing business to deliver personalized, mostly cash‑pay care in the U.S., U.K., EU, and Canada.
The report highlights growth initiatives including new menopause and testosterone offerings, comprehensive lab testing launched in 2025, and a definitive agreement to acquire Australia‑based Eucalyptus to expand into Australia and Japan. As of February 20, 2026, 219,561,143 Class A and 8,377,623 Class V shares were outstanding. Extensive sections outline a complex regulatory environment, compounded‑drug scrutiny, data‑privacy obligations, and detailed risk factors around competition, compliance, supply chain, and international expansion.
Hims & Hers Health reported another year of rapid growth in 2025. Full-year revenue reached
In the fourth quarter, revenue was
Operating cash flow rose to
Hims & Hers Health, Inc. agreed to acquire Australia-based digital health company Eucalyptus for an enterprise value of up to
The structure relies heavily on deferred consideration of approximately
Hims & Hers Health, Inc. reported that institutional investor Capital World Investors beneficially owns 14,322,912 shares of its common stock, representing 6.5% of the class, based on 219,270,891 shares believed to be outstanding as of the ownership date.
Capital World Investors reports sole voting power over 14,316,043 shares and sole dispositive power over 14,322,912 shares, with no shared voting or dispositive power. The shares are stated to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the company.